Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Canntab Therapeutics Ltd CTABF

Canntab Therapeutics Limited is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The Company’s operations comprise a single segment engaged in the medical marijuana business. The Company’s hard pill cannabinoid formulations provide doctors, patients, and... see more

GREY:CTABF - Post Discussion

View:
Post by Newdude on Jan 08, 2019 4:11am

Colombia

Canntab signing of a non-binding Letter of Intent with NewCanna S.A.S of Bogota, Colombia for the establishment of a significant bi-lateral relationship covering the sale and distribution of Canntab’s products in Colombia, Chile, Paraguay and Spain with a one-time, non-refundable license fee ($2 million US) payable to Canntab by NewCanna. Along with the cash, the Colombia deal gives Canntab exposure to Columbian marijuana growers. Growing marijuana in Colombia makes a lot of sense because the plant can be grown year round without power-hungry lights.

Coming at the new world of legalized Canadian cannabis from a pharma background means that Canntab brings an entirely different set of skills to the table. In a crowded market, those skills set Canntab apart. While everyone else is growing cannabis, Canntab is already on the road to creating high value-added medical products.

Comment by Eppy on Jan 11, 2019 12:55pm
If you go back to the original Press Release, the Columbia deal was to be negotiated by November 30.  It is now January 11, and there has been no official update.  Hopefully, we will hear something positive regarding this and the deal that is apparently being negotiated with a company in Mexico,  This later one was supposed to have been completed by the end of December    ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities